Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Símbolo de cotizaciónEBS
Nombre de la empresaEmergent BioSolutions Inc
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoMr. Joseph C. (Joe) Papa
Número de empleados900
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 15
Dirección300 Professional Dr
CiudadGAITHERSBURG
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal20879
Teléfono12406313200
Sitio Webhttps://emergentbiosolutions.com/
Símbolo de cotizaciónEBS
Fecha de salida a bolsaNov 15, 2006
Director ejecutivoMr. Joseph C. (Joe) Papa
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos